Related Experiment Video
Updated: Jul 27, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Population pharmacokinetic meta-analysis with efavirenz
J S Barrett1, A S Joshi, M Chai
1Drug Metabolism and Pharmacokinetics Department, DuPont Pharmaceuticals, Newark, DE, USA. jeff.barrett@aventis.com
Summary
A population pharmacokinetic model for efavirenz was developed using Phase I data. Efavirenz clearance varies by dose, race, sex, and drug interactions, but dose adjustments are not typically needed.
Area of Science:
- Pharmacokinetics
- Drug Metabolism
- Population Modeling
Background:
- Efavirenz is a key antiretroviral medication.
- Understanding efavirenz pharmacokinetics is crucial for optimizing treatment.
- Previous studies have provided insights into efavirenz behavior in the body.
Purpose of the Study:
- To develop a population pharmacokinetic (PK) model for efavirenz.
- To characterize efavirenz PK variability in healthy volunteers.
- To identify factors influencing efavirenz exposure.
Main Methods:
- A population PK model was built using data from 16 Phase I studies.
- Data included 334 healthy volunteers and 9,342 plasma concentrations.
- NONMEM software was used for model development and validation.
Main Results:
- A two-compartment model with first-order absorption was utilized.
- Clearance was higher with multiple-dose exposure compared to single-dose.
- Clearance varied by dose, administration frequency, race, sex, and co-administered drugs.
Conclusions:
- The developed population PK model accurately describes efavirenz pharmacokinetics.
- Identified covariates (race, sex, drug interactions) had minimal impact on clearance, not warranting dose adjustments.
- The model is suitable for further evaluation in HIV-infected patients.
More Related Videos
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:30Measurement of Bioavailability: Pharmacokinetic Methods
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
01:20Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.